Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash from Financing Activities (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Cash from Financing Activities for 5 consecutive years, with $2.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 27.04% to $2.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.0 million, a 7.54% decrease, with the full-year FY2024 number at $17.9 million, up 63.65% from a year prior.
  • Cash from Financing Activities was $2.8 million for Q3 2025 at Vivos Therapeutics, down from $3.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $25.4 million in Q2 2021 to a low of -$1.2 million in Q3 2021.
  • A 4-year average of $5.6 million and a median of $3.6 million in 2023 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 1904.8% in 2021; the steepest drop was 164.4% in 2021.
  • Vivos Therapeutics' Cash from Financing Activities stood at -$1.2 million in 2021, then surged by 403.92% to $3.6 million in 2023, then fell by 14.41% to $3.1 million in 2024, then decreased by 9.53% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Cash from Financing Activities are $2.8 million (Q3 2025), $3.1 million (Q4 2024), and $3.8 million (Q3 2024).